TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).-MedSci.cn

TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).

Porta, C; Verzoni, E; Escudier, B; Pal, SK; Atkins, MB; Hutson, TE; Needle, MN; McDermott, DF; Rini, BI

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务